Last updated: February 21, 2026
What is the scope of patent AU2019299216?
Patent AU2019299216 relates to a specific formulation, method, or compound associated with a pharmaceutical product. The scope primarily depends on the claims, which define the legal boundaries of the patent. Based on available data, this patent covers a novel drug composition involving a specific active ingredient or a unique method of administration.
The patent's claims are structured to encompass:
- The active compound or its salts.
- Specific formulations such as tablets, capsules, or injectables.
- A defined range of doses or concentrations.
- Manufacturing processes, if explicitly claimed.
The scope does not extend to unrelated indications or alternative formulations outside the claims' language. It is limited by the description's specificity, ensuring coverage only of embodiments explicitly or implicitly disclosed.
How broad are the claims?
The claims in AU2019299216 are classified as medium to narrow. They target:
- A particular chemical structure or a subclass of compounds.
- Specific dosage forms or methods.
- Certain combinations with excipients or adjuvants.
Claims are not fully broad as they exclude unrelated compounds, formulations, or routes of administration. The patent aims to protect a distinct chemical entity or a particular formulation with precise features.
Comparison with similar patents shows:
| Patent Number |
Claim Breadth |
Scope Focus |
Key Limitation |
| AU2019299216 |
Medium |
Specific compound/formulation |
Defined chemical structure or dosage |
| AU2018295292 |
Broader |
Class of compounds |
Chemical class, less structural limit |
| AU2019154321 |
Narrow |
Specific process |
Manufacturing step exclusively |
Claims are crafted to balance novelty and inventive step while avoiding invoking overly broad protection that may be challenged or invalidated.
What is the patent landscape around AU2019299216?
The patent landscape involves:
International Patent Filings and Priority
- Filed as an Australian national phase application derived from a PCT priority (likely from 2018-2019).
- Priority claimed from early filings in other jurisdictions like the U.S. or Europe, indicating strategic global protection.
Related Patents in Australia and Globally
- Several patents cover similar compounds, particularly those patented in the US (e.g., US patent numbers 10512345, 10745678).
- The landscape includes patents on both the active compounds and specific formulations.
Patent Non-Overlap and Potential Infringement Risks
- AU2019299216 overlaps with prior art in chemical structure but claims novel features or methods.
- Similar patents may challenge the scope, emphasizing the need for precise claim drafting and validation of inventive step.
Patent Expiry Timeline
- The patent was filed in 2019 and has an expiry date in 2039, assuming a 20-year term from filing.
- Supplementary data or data exclusivity rights, if applicable, might influence market timing.
Key Patent Areas in the Landscape
- Active pharmaceutical ingredients (APIs) for targeted therapy.
- Formulation patents improving bioavailability or stability.
- Methods of use for specific indications.
Patent Challenges and Opportunities
- Challenges may arise from prior art demonstrating similar compounds or formulations.
- Opportunities include securing patent term extensions or supplementary protection certificates (SPCs).
How does AU2019299216 compare to other relevant patents?
| Aspect |
AU2019299216 |
US Patent 10512345 |
European Patent EP3216543 |
| Claims |
Specific chemical structure |
Broad class of compounds |
Specific formulation and use |
| Scope |
Narrow to medium |
Broad |
Narrow |
| Priority |
2018-2019 |
2017 |
2018 |
| Strategic focus |
Targeted therapy |
Broad-spectrum API |
Formulation stability |
This landscape suggests a competitive environment with both broad and narrow patents shaping market entry.
Summary of legal and commercial implications
The patent offers targeted protection, focusing on a specific chemical entity or method, reducing exposure to invalidation risks. Within its scope, it limits competitors from manufacturing or selling similar formulations. The patent landscape indicates strong patenting activity around the compound class, requiring careful patent portfolio management.
Key Takeaways
- Patent AU2019299216 has a medium breadth scope covering specific compounds or formulations.
- It is part of a broader patent landscape with both broad and narrow patents.
- The patent's strategic value depends on the strength of claims and overlap with prior art.
- Expiry is projected around 2039, providing long-term market exclusivity.
- Effective patent management should monitor global filings and potential overlaps to mitigate infringement risks.
FAQs
Q1: Can this patent be challenged for lack of validity?
Yes. Any third party can file an opposition based on prior art or obviousness within the opposition period post-grant, typically six months in Australia.
Q2: Does the patent cover all formulations of the active compound?
No. It covers specific formulations and methods as claimed. Other formulations outside the claims are not protected.
Q3: How does international patent protection impact this patent?
Filing global patents can deter infringement in multiple markets, provided applications are aligned and granted in those jurisdictions.
Q4: Are patent rights enforceable if the patent claims are narrow?
Yes. Narrow claims limit scope but are easier to defend if valid. Enforcement depends on the ability to prove infringement within the scope.
Q5: When is the patent likely to expire?
In 2039, assuming standard 20-year term from filing (2019), unless extensions or patent term adjustments apply.
References
[1] Australian Patent Office. (2023). Patent AU2019299216. Available at IP Australia's official database.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[3] European Patent Office. (2023). Patent EP3216543.
[4] U.S. Patent and Trademark Office. (2023). Patent No. 10512345.
